IGOR VOLKOV: Open Payments
NPI 1588810162 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,052 in 39 payments from 8 companies in 2025. Trend: 2023 $2,009 · 2024 $3,343 · 2025 $2,052
Food & beverage: $2,052
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 7 | $355 |
| Neurocrine BioSciences, Inc. | 5 | $338 |
| Alkermes, Inc. | 7 | $338 |
| Janssen Pharmaceuticals, Inc | 6 | $278 |
| Vanda Pharmaceuticals Inc. | 2 | $222 |
| Teva Pharmaceuticals USA, Inc. | 4 | $191 |
| Otsuka America Pharmaceutical, Inc. | 6 | $188 |
| ABBVIE INC. | 2 | $142 |
Products named: COBENFY, INGREZZA, INVEGA SUSTENNA, ARISTADA, FANAPT, UZEDY, VRAYLAR, ABILIFY MAINTENA.
Industry payments across DC — which companies pay providers there.
